OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.9 EUR -4.07% Market Closed
Market Cap: 129.4m EUR

OSE Immunotherapeutics SA
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Total Other Income
€1.4m
CAGR 3-Years
392%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Total Other Income
-€4k
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Total Other Income
€1k
CAGR 3-Years
-71%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Total Other Income
€891k
CAGR 3-Years
103%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Total Other Income
€6.9m
CAGR 3-Years
N/A
CAGR 5-Years
150%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Total Other Income
€1.9m
CAGR 3-Years
95%
CAGR 5-Years
N/A
CAGR 10-Years
58%

OSE Immunotherapeutics SA
Glance View

Market Cap
128.4m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.94 EUR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Total Other Income?
Total Other Income
1.4m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Total Other Income amounts to 1.4m EUR.

What is OSE Immunotherapeutics SA's Total Other Income growth rate?
Total Other Income CAGR 3Y
392%

Over the last year, the Total Other Income growth was 2 760%. The average annual Total Other Income growth rates for OSE Immunotherapeutics SA have been 392% over the past three years .

Back to Top